Just 6% of cardiologists are currently prescribing PCSK9is, despite 97% believing in their abilities. More: Survey reveals ‘key barriers’ limiting PCSK9is prescribing Source: News
read moreNovartis CEO Vas Narasimhan has been touting an “unbossed” management environment at the Swiss drugmaker. To hear chief digital officer Bertrand Bodson tell it, part of that effort includes arming employees with digital solutions. More: Novartis digital chief is turning
read moreSwiss CDMO Lonza is extending the Chinese New Year break at its four plants in China, but not to celebrate. The unplanned extension is a precaution as coronavirus continues to spread rapidly through the country. More: Lonza keeps Chinese plants
read moreFrench authorities have spent more than three years investigating whether Sanofi downplayed the danger of birth defects linked to its valproate-based anti-epilepsy med Depakine. Now, that probe has materialized into actual charges—but it might not land Sanofi in the courtroom. More: Sanofi
read moreResearchers had high hopes for an HIV vaccine candidate made up of components supplied by GlaxoSmithKline and Sanofi. But several years into the study, researchers took a peek at the data in January. It wasn’t working. More: High hopes dashed:
read moreTakeda had expected to report an operating loss this fiscal year. But thanks to faster integration with Shire, it’s now looking at a possible profit. Don’t expect any contribution from Natpara in the U.S., though, Takeda’s chief financial officer said—the
read more© 1994 - 2026 B.M. Pharmaceuticals